ClinicalTrials.gg

TargetBeta

CHRM3

cholinergic receptor muscarinic 3 · also m3AChR · Cholinergic receptors muscarinic

7 programs in company-led studies act on CHRM3, from 5 companies: 1 in phase 3, 4 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
trospiumruleBristol-Myers Squibbphase 42118 runningCHRM2ChEMBL
trospium chlorideruleBristol-Myers Squibbphase 4157 runningCHRM2ChEMBL
GlycopyrrolateruleNovartisphase 4873 runningCHRM1, CHRM2, CHRM4, CHRM5ChEMBL
umeclidinium bromideruleGlaxoSmithKlinephase 471 running–ChEMBL
AtropineruleLaboratorios Sophia S.A de C.V.phase 3176 runningCHRM1, CHRM2ChEMBL
TQC3927Sino Biopharmaceuticalphase 230 runningADRB2the company's pipeline
TQC3302Sino Biopharmaceuticalphase 110 runningADRB2, NR3C1the company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.